Plant Name: Annona reticulata
Taxonomic Information:
Plant ID: NPO9632
Plant Latin Name: Annona reticulata
Taxonomy Genus: Annona
Taxonomy Family: Annonaceae
Plant External Links:
NCBI TaxonomyDB:
301862
Plant-of-the-World-Online:
72295-1
Used in Medicines:
Country/Region:
Thailand; Indonesia; IndiaTraditional Medicine System:
Geographical Distribution:
Brazil; Bangladesh; Guinea; Costa Rica; Cambodia; Bahamas; Ethiopia; Peru; Vanuatu; Bolivia; Venezuela; Ecuador; Cuba; El Salvador; Cape Verde; Guatemala; Thailand; Dominican Republic; Belize; Indonesia; Mauritius; Trinidad and Tobago; Haiti; Jamaica; Seychelles; Honduras; Mexico; India; Senegal; Colombia; Nicaragua
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| DRD3; DRD2; | |
| HSD17B10; | |
| HIF1A; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Small molecule receptor (family A GPCR) | DRD3 | Dopamine D3 receptor | P35462 | CHEMBL234 |
| Small molecule receptor (family A GPCR) | DRD2 | Dopamine D2 receptor | P14416 | CHEMBL217 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0007610; behavior | GO:0008542; visual learning | 5.751E-08 | 7.003E-04 | DRD2, DRD3, HIF1A |
| BP | GO:0009987; cellular process | GO:0060160; negative regulation of dopamine receptor signaling pathway | 9.649E-08 | 7.003E-04 | DRD2, DRD3 |
| BP | GO:0040011; locomotion | GO:0090325; regulation of locomotion involved in locomotory behavior | 3.216E-07 | 1.400E-03 | DRD2, DRD3 |
| BP | GO:0023052; signaling | GO:0051584; regulation of dopamine uptake involved in synaptic transmission | 9.002E-07 | 2.450E-03 | DRD2, DRD3 |
| MF | GO:0060089; molecular transducer activity | GO:0001591; dopamine neurotransmitter receptor activity, coupled via Gi/Go | 9.002E-07 | 2.450E-03 | DRD2, DRD3 |
| BP | GO:0009987; cellular process | GO:0007195; adenylate cyclase-inhibiting dopamine receptor signaling pathway | 1.447E-06 | 2.864E-03 | DRD2, DRD3 |
| BP | GO:0050896; response to stimulus | GO:0034776; response to histamine | 1.768E-06 | 2.961E-03 | DRD2, DRD3 |
| BP | GO:0009987; cellular process | GO:0002031; G-protein coupled receptor internalization | 1.768E-06 | 2.961E-03 | DRD2, DRD3 |
| BP | GO:0050896; response to stimulus | GO:0060134; prepulse inhibition | 2.507E-06 | 3.211E-03 | DRD2, DRD3 |
| BP | GO:0032501; multicellular organismal process | GO:0035815; positive regulation of renal sodium excretion | 2.507E-06 | 3.211E-03 | DRD2, DRD3 |
| MF | GO:0005488; binding | GO:0035240; dopamine binding | 2.507E-06 | 3.211E-03 | DRD2, DRD3 |
| BP | GO:0032501; multicellular organismal process | GO:0045187; regulation of circadian sleep/wake cycle, sleep | 5.494E-06 | 5.250E-03 | DRD2, DRD3 |
| BP | GO:0007610; behavior | GO:0048148; behavioral response to cocaine | 6.104E-06 | 5.250E-03 | DRD2, DRD3 |
| BP | GO:0008283; cell proliferation | GO:0002052; positive regulation of neuroblast proliferation | 6.104E-06 | 5.250E-03 | DRD2, HIF1A |
| BP | GO:0051179; localization | GO:0050482; arachidonic acid secretion | 8.126E-06 | 5.362E-03 | DRD2, DRD3 |
| BP | GO:0050896; response to stimulus | GO:0001975; response to amphetamine | 1.044E-05 | 6.458E-03 | DRD2, DRD3 |
| BP | GO:0008152; metabolic process | GO:0042417; dopamine metabolic process | 1.214E-05 | 6.600E-03 | DRD2, DRD3 |
| BP | GO:0009987; cellular process | GO:0014059; regulation of dopamine secretion | 1.214E-05 | 6.600E-03 | DRD2, DRD3 |
| BP | GO:0050896; response to stimulus | GO:0010039; response to iron ion | 1.493E-05 | 6.933E-03 | DRD2, HIF1A |
| BP | GO:0065007; biological regulation | GO:0007194; negative regulation of adenylate cyclase activity | 1.592E-05 | 6.933E-03 | DRD2, DRD3 |
| BP | GO:0050896; response to stimulus | GO:0043278; response to morphine | 1.592E-05 | 6.933E-03 | DRD2, DRD3 |
| CC | GO:0044464; cell part | GO:0042995; cell projection | 1.402E-03 | 1.183E-01 | DRD2, DRD3, HIF1A |
| CC | GO:0043226; organelle | GO:0097730; non-motile cilium | 6.611E-03 | 3.129E-01 | DRD2 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09150 Organismal Systems | 09156 Nervous system | hsa04728 | Dopaminergic synapse | 2.456E-04 | 4.666E-03 | DRD2, DRD3 |
| 09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04080 | Neuroactive ligand-receptor interaction | 1.126E-03 | 1.070E-02 | DRD2, DRD3 |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00280 | Valine, leucine and isoleucine degradation | 9.566E-03 | 3.619E-02 | HSD17B10 |
| 09160 Human Diseases | 09164 Substance dependence | hsa05030 | Cocaine addiction | 9.765E-03 | 3.619E-02 | DRD2 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04150 | mTOR signaling pathway | 1.195E-02 | 3.619E-02 | HIF1A |
| 09160 Human Diseases | 09161 Cancers | hsa05211 | Renal cell carcinoma | 1.314E-02 | 3.619E-02 | HIF1A |
| 09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 1.333E-02 | 3.619E-02 | HIF1A |
| 09160 Human Diseases | 09161 Cancers | hsa05231 | Choline metabolism in cancer | 2.005E-02 | 3.884E-02 | HIF1A |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04540 | Gap junction | 1.749E-02 | 3.884E-02 | DRD2 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 2.044E-02 | 3.884E-02 | HIF1A |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cocaine addiction | F14.2 | DRD3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | DRD3; |
| K00-K95: Diseases of the digestive system | Gastric motility disorder | K22.4 | DRD3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | DRD3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | DRD3; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Emesis | R11 | DRD3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | DRD3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Male sexual disorders | F52 | DRD3; |
>> Profiles of ingredients and activity landscape
>> Targets derived from weak experimental activities
